HealthyNCT01988545
GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow
A study testing 1,5 nmol/kg,GLP-1 sc injection, 1,5 nmol/kg GLP-1 9-36amide, sc injection and Exendin-4 ;10 ug,sc injection in people with Healthy, run by Zealand University Hospital at 1 site in Denmark.
Trial summary
to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters Read more about this study
- Who is it for?
- Ages 20 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- 1,5 nmol/kg,GLP-1 sc injection, 1,5 nmol/kg GLP-1 9-36amide, sc injection and Exendin-4 ;10 ug,sc injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 8 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Nov 2013to 1 Dec 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- healthy subjects
Who cannot join
- medical conditions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: GLP-1's Influence on Intestinal Blood Flow
to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters
Read the detailed description
to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters, in healthy subjects, 4 arms, task force monitor
- Conditions
- Healthy
- Being tested
- 1,5 nmol/kg,GLP-1 sc injection, 1,5 nmol/kg GLP-1 9-36amide, sc injection, Exendin-4 ;10 ug,sc injection, saline
- Keywords
- GLP-1, blood flow, cardiac out put, stroke volume, beat to beat, effect of GLP-1 on cardiac parameters and blood flow
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
1,5 nmol/kg,GLP-1 sc injectionOther
Also called native GLP-1
1,5 nmol/kg GLP-1 9-36amide, sc injectionOther
Exendin-4 ;10 ug,sc injectionOther
salineOther
| Study group | Role | What they receive |
|---|---|---|
| GLP-1 | Active comparator | 1,5 nmol/kg,GLP-1 sc injection Receives: Other: 1,5 nmol/kg GLP-1 9-36amide, sc injection; Other: Exendin-4 ;10 ug,sc injection |
| GLP-1 9-36amide | Active comparator | 1,5 nmol/kg GLP-1 9-36amide, sc injection Receives: Other: 1,5 nmol/kg,GLP-1 sc injection; Other: Exendin-4 ;10 ug,sc injection |
| Exendin-4 | Active comparator | Exendin-4 ;10 ug,sc injection Receives: Other: 1,5 nmol/kg,GLP-1 sc injection; Other: 1,5 nmol/kg GLP-1 9-36amide, sc injection |
| isotonic saline | Placebo comparator | 2 ml of isotonic saline, sc injection Receives: Other: 1,5 nmol/kg,GLP-1 sc injection; Other: 1,5 nmol/kg GLP-1 9-36amide, sc injection; Other: saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
blood flow
blood flow change measured by ultra sound
Measured: with in 120 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2013 (estimated)
- Study start1 Nov 2013
- Primary completionJun 2014
- Study completion1 Dec 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Zealand University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zealand University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Copenhagen, Glostrup University Hospital, Copenhagen
- Responsible party
- Principal investigator, lasse bremholm hansen, Zealand University Hospital
- Investigators
- Lasse Bremholm, MD, ph.d., Principal investigator, Køge Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01988545
- Sponsor's protocol ID
- 2013.GLP-1
- Status last verified
- Nov 2013
- First submitted
- 13 Nov 2013
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GLP-1's Influence on Intestinal Blood Flow
- ClinicalTrials.gov ID
- NCT01988545
- Acronym / sponsor ID
- 2013.GLP-1
- Conditions
- Healthy
- Keywords
- GLP-1, blood flow, cardiac out put, stroke volume, beat to beat, effect of GLP-1 on cardiac parameters and blood flow
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Zealand University HospitalUniversity, hospital or other
- Collaborators
- University of Copenhagen, Glostrup University Hospital, Copenhagen
- Study start
- 1 Nov 2013 (actual)
- Primary completion
- Jun 2014 (actual)
- Study completion
- 1 Dec 2014 (actual)
- First posted
- 20 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters
Detailed description
to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters, in healthy subjects, 4 arms, task force monitor
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| GLP-1 | Active comparator | Other: 1,5 nmol/kg GLP-1 9-36amide, sc injection, Other: Exendin-4 ;10 ug,sc injection1,5 nmol/kg,GLP-1 sc injection |
| GLP-1 9-36amide | Active comparator | Other: 1,5 nmol/kg,GLP-1 sc injection, Other: Exendin-4 ;10 ug,sc injection1,5 nmol/kg GLP-1 9-36amide, sc injection |
| Exendin-4 | Active comparator | Other: 1,5 nmol/kg,GLP-1 sc injection, Other: 1,5 nmol/kg GLP-1 9-36amide, sc injectionExendin-4 ;10 ug,sc injection |
| isotonic saline | Placebo comparator | Other: 1,5 nmol/kg,GLP-1 sc injection, Other: 1,5 nmol/kg GLP-1 9-36amide, sc injection, Other: saline2 ml of isotonic saline, sc injection |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- healthy subjects
Key exclusion criteria (1 listed)
- medical conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 1,5 nmol/kg,GLP-1 sc injectionAlso: native GLP-1 | Other | Exendin-4, GLP-1 9-36amide, isotonic saline |
| 1,5 nmol/kg GLP-1 9-36amide, sc injection | Other | Exendin-4, GLP-1, isotonic saline |
| Exendin-4 ;10 ug,sc injection | Other | GLP-1, GLP-1 9-36amide |
| saline | Other | isotonic saline |
Primary outcome
blood flow
Time frame: with in 120 minutes
blood flow change measured by ultra sound
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
Related trials for Healthy
Active, not recruitingObservational study
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
Spinal Cord Injuries, Traumatic Spinal Cord Injury
Recruiting
Effects of a Hemp Seed-based Product on Appetite and Health Parameters
Healthy
RecruitingPhase 1
A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH
Metabolic Dysfunction-Associated Steatohepatitis
Not yet recruitingPhase 1
Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)
Healthy Volunteers
Not yet recruiting
Stearic Acid and Endothelial Function
Healthy Middle-aged Subjects, Obesity & Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lasse Bremholm, MD, ph.d. principal investigator
Køge Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 1,5 nmol/kg,GLP-1 sc injection, 1,5 nmol/kg GLP-1 9-36amide, sc injection and Exendin-4 ;10 ug,sc injection in people with Healthy, run by Zealand University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
blood flow (time frame: with in 120 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.